Filter By:

IAVI Report

IAVI Report is a scientific publication that provides comprehensive and editorially independent coverage of HIV vaccine and prevention research, as well as the quest to develop vaccines and other preventive technologies to address other global health priorities. It features the voices and opinions of those leading these efforts and provides an unparalleled analysis of the latest scientific and policy research.

To see recent full issues of IAVI Report, click here.

To access archived issues of IAVI Report dating back to 1996, click here.

Subscribe now to receive IAVI Report right to your inbox.

Questions/comments? Email us at iavireport@iavi.org.

Key Words Search

Exploring adjuvants to boost durability of mRNA vaccines

COVID-19 has validated the use of mRNA vaccines but researchers are still exploring how to improve the durability of the antibody responses they induce. Bali Pulendran discusses how adjuvants are one approach to achieving longer-lasting immune responses against COVID-19 and other pathogens.

Data cabinets
in the cloud

IAVI’s DataSpace platform is making the information collected in landmark studies more widely available to the research community.

mRNA vaccines: Manufacturing in Africa

A South African biotech aims to produce the first African-developed, African-made mRNA vaccine, and to train researchers and developers from 16 similar would-be vaccine makers to do the same. Part two of a three-part series.

Is the next pandemic really preventable?

COVID-19 has inspired many books about pandemic prevention. If anything, this latest pandemic should shore up our willingness to prevent, prepare for, and respond to future infectious disease outbreaks. But reports show the world isn’t any better prepared today than it was before.

Unraveling the mysteries of a vaccine vector

Persistence pays. After decades, researchers identify an unusual mechanism for how a potential HIV vaccine vector works in animals. Will it also work in humans?

mRNA:
An HIV vaccine platform?

For HIV, there are currently several formulations of experimental vaccines in early-stage human clinical trials. Apart from some overlap in strategy, they have one main thing in common — they rely on mRNA.

Jon Cohen on
covering COVID-19

When SARS-CoV-2 emerged, Jon Cohen simply did what he always does as a science journalist. But this time his work had a dual purpose — his process was also being filmed as part of the documentary How to Survive a Pandemic.

From the editor

A new
IAVI Report

The past, present, and future of IAVI

A conversation with Seth
Berkley and Mark Feinberg

40 years
of AIDS
vaccine
research

A timeline of major milestones in the decades-long effort to develop an HIV vaccine.

Vaccines:
adapting to
the times

Over hundreds of years, researchers have matched contemporary scientific tools to address the infectious disease threats of their times.

About

Our Work

Our Science

News & Resources

©2022 International AIDS Vaccine Initiative. International AIDS Vaccine Initiative^®, IAVI^®, and the IAVI logo^® are registered trademarks of the International AIDS Vaccine Initiative, Inc.